Barclays Issues Positive Forecast for Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price

Key Points

• Barclays raised its Iovance Biotherapeutics price target from $18 to $19 and maintained an Overweight rating, implying roughly 143% upside from the prior close.
• Analyst views are generally positive: MarketBeat reports a consensus “Moderate Buy” rating and an average price target of $13.80.
• Iovance’s latest quarter beat expectations, with revenue of about $121.5 million and a loss of $0.05 per share, versus estimates of $116 million and a $0.09 loss.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) had its price objective lifted by investment analysts at Barclays from $18.00 to $19.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has an "overweight" rating on the biotechnology company's stock. Barclays's price objective would suggest a potential upside of 143.00% from the company's previous close.

IOVA has been the subject of a number of other research reports. Wells Fargo & Company upped their price objective on Iovance Biotherapeutics from $14.00 to $18.00 and gave the stock an "overweight" rating in a research note on Wednesday, September 30th. Robert W. Baird boosted their price target on Iovance Biotherapeutics from $6.00 to $11.00 and gave the stock a "neutral" rating in a report on Thursday, October 8th. HC Wainwright upped their price target on Iovance Biotherapeutics from $9.00 to $20.00 and gave the stock a "buy" rating in a research note on Tuesday, September 29th. UBS Group upped their price target on Iovance Biotherapeutics from $7.00 to $8.00 and gave the stock a "neutral" rating in a research note on Tuesday. Finally, Citizens Jmp increased their price objective on shares of Iovance Biotherapeutics from $8.00 to $12.00 and gave the company a "market outperform" rating in a report on Friday. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $13.80.

Iovance Biotherapeutics Trading Up 1.0%

Iovance Biotherapeutics stock traded up $0.08 during mid-day trading on Friday, hitting $7.82. The stock had a trading volume of 3,440,369 shares, compared to its average volume of 15,785,990. Iovance Biotherapeutics has a one year low of $2.08 and a one year high of $15.37. The firm has a market capitalization of $3.54 billion, a P/E ratio of -10.69 and a beta of 0.88. The firm's 50 day moving average is $11.38 and its 200 day moving average is $5.94.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.04. The business had revenue of $121.47 million for the quarter, compared to analysts' expectations of $115.98 million. Iovance Biotherapeutics had a negative return on equity of 40.51% and a negative net margin of 89.11%. The firm's quarterly revenue was up 64.8% on a year-over-year basis. As a group, equities research analysts forecast that Iovance Biotherapeutics will post -0.45 earnings per share for the current year.

Institutional Investors Weigh In On Iovance Biotherapeutics

Several large investors have recently made changes to their positions in IOVA. BlackRock Inc. bought a new stake in shares of Iovance Biotherapeutics in the 2nd quarter valued at approximately $153,744,000. Palo Alto Investors LP purchased a new position in shares of Iovance Biotherapeutics in the 2nd quarter worth approximately $22,032,229. Bank of America Corp DE purchased a new position in shares of Iovance Biotherapeutics in the 2nd quarter worth approximately $20,773,000. Knott David M Jr bought a new position in shares of Iovance Biotherapeutics during the 1st quarter valued at approximately $5,616,000. Finally, Rice Hall James & Associates LLC bought a new position in shares of Iovance Biotherapeutics during the 2nd quarter valued at approximately $6,406,000. 77.03% of the stock is owned by institutional investors.

Key Headlines Impacting Iovance Biotherapeutics

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Q3 results topped expectations. Iovance reported about $122 million in revenue, a record, and a loss of $0.05 per share versus the $0.09 loss analysts expected. Amtagvi sales drove growth, gross margin rose to about 60%, and lower R&D costs helped improve results. The company reaffirmed its 2026 revenue outlook. Article: IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs
• Positive Sentiment: Sarcoma program gained regulatory momentum. Lifileucel received FDA Fast Track designation following strong sarcoma trial data. Iovance also reported a 55.6% response rate in UPS and DDLPS, with a registrational trial underway. Article: Iovance Biotherapeutics Lifileucel Wins Fast Track After Strong Sarcoma Trial Data
• Neutral Sentiment: An analyst upgraded the stock to Buy after resetting expectations, citing momentum in the Amtagvi melanoma launch. The analyst also cautioned that the opportunity in lung cancer may have been overestimated. Article: Iovance: Reset Expectations Make The Stock a Buy Again
• Negative Sentiment: Lung-cancer data remain a risk. Lifileucel showed a 24.6% response rate across 69 evaluable non-squamous NSCLC patients, slightly below an earlier interim result. The reported 59.1% response rate in a biomarker-selected subgroup is more encouraging, but the treatment’s broader potential remains uncertain. Article: Iovance Reports Q3 2026 Results and Updates

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc NASDAQ: IOVA is a biotechnology company focused on developing and commercializing personalized cell therapies for patients with cancer. Its technology is based on tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient's tumor, expanded outside the body, and reinfused to help attack cancer cells.

The company's lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.